Omega TherapeuticsNASDAQ: OMGA

VANCOUVER, BC / ACCESSWIRE / October 28, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce additional assay results from its 2024 drill program at the Williams Property in British Columbia's Golden Horseshoe. Drill Hole WM22-02-extension ("ext") significantly extended mineralization and continued the strong intervals from the property's previous campaign (Figure 1).

CAMBRIDGE, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will share new preclinical data at three upcoming scientific meetings.

VANCOUVER, BC / ACCESSWIRE / September 18, 2024 / Omega Pacific Resources Inc. (CSE:OMGA) ("Omega" or the "Company") announces that further to its news release dated May 24, 2024, the Company has issued 71,500 common shares to Steven Scott for three mineral exploration claims located in the Golden Horseshoe Area in British Columbia covering 51.716 hectares pursuant to an asset purchase agreement dated May 22, 2024 and amended on September 13, 2024. These common shares were issued on September 18, 2024 and are subject to the statutory four month and one date hold period, which expires on January 19, 2025.

CAMBRIDGE, Mass., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced the publication of preclinical data from studies of OTX-2002 in Nature Communications. The article highlights the potential of Omega's approach to precision epigenomic control and the ability of OTX-2002 to controllably regulate the historically undruggable MYC gene in multiple models of hepatocellular carcinoma (HCC), the most common type of primary liver cancer.

VANCOUVER, BC / ACCESSWIRE / August 8, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega Pacific" or the "Company") is pleased to announce additional drill results from its 2024 drill program at the Williams Property in British Columbia's Golden Horseshoe. Assay results from Phase One's second drill hole (WM24-02) continue to demonstrate high-grade and bulk tonnage mineralization (Figure 1).

Omega Therapeutics, Inc. (OMGA) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.54 per share a year ago.

CAMBRIDGE, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent Company progress.

VANCOUVER, BC / ACCESSWIRE / July 9, 2024 / Omega Pacific Resources Inc. (CSE:OMGA)(OTCQB:OMGPF)(FSE:Q0F) ("Omega" or the "Company") is pleased to provide an overview of the newly acquired Williams Project ("Williams") located in British Columbia's Golden Horseshoe. The property is a 11,490 ha, high-grade land package with over 11,000 m of historical drilling, positioned 330 km north of Smithers, BC.

Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing